Research Analysts Set Expectations for AURA FY2030 Earnings

Aura Biosciences, Inc. (NASDAQ:AURA) – HC Wainwright issued their FY2030 earnings estimates for Aura Biosciences in a note issued to investors on Monday, March 30th. HC Wainwright analyst A. Maldonado forecasts that the company will post earnings per share of ($0.35) for the year. HC Wainwright currently has a “Buy” rating and a $22.00 target price on the stock. The consensus estimate for Aura Biosciences’ current full-year earnings is ($1.66) per share.

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Aura Biosciences in a report on Friday, March 27th. Three research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Aura Biosciences presently has an average rating of “Hold” and a consensus price target of $20.50.

Aura Biosciences Stock Performance

Shares of Aura Biosciences stock opened at $6.70 on Thursday. The company has a market capitalization of $429.81 million, a P/E ratio of -3.74 and a beta of 0.35. Aura Biosciences has a 1 year low of $4.34 and a 1 year high of $7.48. The company’s fifty day moving average is $5.90 and its two-hundred day moving average is $5.87.

Aura Biosciences (NASDAQ:AURA) last released its quarterly earnings results on Monday, March 30th. The company reported ($0.37) EPS for the quarter, beating the consensus estimate of ($0.43) by $0.06.

Institutional Investors Weigh In On Aura Biosciences

A number of institutional investors have recently added to or reduced their stakes in the business. Tower Research Capital LLC TRC increased its position in Aura Biosciences by 49.3% during the 2nd quarter. Tower Research Capital LLC TRC now owns 6,372 shares of the company’s stock worth $40,000 after purchasing an additional 2,104 shares during the period. ProShare Advisors LLC acquired a new stake in shares of Aura Biosciences in the 4th quarter valued at approximately $59,000. Water Island Capital LLC purchased a new stake in shares of Aura Biosciences in the third quarter valued at approximately $64,000. 49 Wealth Management LLC acquired a new position in Aura Biosciences during the third quarter worth $66,000. Finally, Invesco Ltd. purchased a new position in Aura Biosciences in the second quarter worth $76,000. Hedge funds and other institutional investors own 96.75% of the company’s stock.

Insider Activity

In related news, insider Conor Kilroy sold 12,079 shares of Aura Biosciences stock in a transaction on Tuesday, February 17th. The shares were sold at an average price of $5.05, for a total value of $60,998.95. Following the transaction, the insider directly owned 167,234 shares in the company, valued at $844,531.70. This trade represents a 6.74% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, SVP Amy Elazzouzi sold 8,549 shares of the business’s stock in a transaction on Tuesday, February 17th. The shares were sold at an average price of $5.06, for a total transaction of $43,257.94. Following the completion of the transaction, the senior vice president directly owned 75,532 shares in the company, valued at $382,191.92. This represents a 10.17% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 123,076 shares of company stock valued at $618,783. 6.30% of the stock is currently owned by company insiders.

Aura Biosciences Company Profile

Aura Biosciences is a clinical‐stage biopharmaceutical company focused on the development of novel virus‐like particle (VLP) therapies for the treatment of cancer. By combining proprietary VLP technology with photoactivatable dyes, Aura aims to deliver highly selective photodynamic therapies that target and destroy tumor cells while sparing healthy tissue. The company’s platform is designed to address solid tumors in both ophthalmic and non‐ophthalmic settings, leveraging precision activation via near‐infrared light to induce localized tumor cell apoptosis and stimulate anti‐tumor immune responses.

The lead product candidate, AU-011, is being evaluated in patients with choroidal melanoma, a rare but potentially sight-threatening eye cancer.